BICYCLE THERAPEUTICS PLC - 8-K Filing
Bicycle Therapeutics announced initial data from the Duravelo-2 trial for zelenectide pevedotin (zelenectide) in metastatic urothelial cancer at ASCO 2026. The optimal dose showed a 65% overall response rate and lower toxicity compared to standard of care, with no Grade 4 or 5 adverse events reported. (Items: 8.01 Other Events On May 21, 2026, Bicycle Therapeutics plc (the “Company”) issued a press release announcing initial Duravelo-2 data for metastat, 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No)
Tickers: $BCYC